Hologic, Inc. (NASDAQ:HOLX) Director Lawrence M. Levy sold 9,596 shares of Hologic stock in a transaction on Tuesday, October 10th. The stock was sold at an average price of $36.81, for a total value of $353,228.76. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Lawrence M. Levy also recently made the following trade(s):
- On Thursday, September 7th, Lawrence M. Levy sold 7,139 shares of Hologic stock. The stock was sold at an average price of $39.04, for a total value of $278,706.56.
Shares of Hologic, Inc. (HOLX) opened at 36.28 on Friday. The company has a market capitalization of $10.18 billion, a PE ratio of 13.51 and a beta of 0.91. Hologic, Inc. has a 12-month low of $35.15 and a 12-month high of $46.80. The stock’s 50 day moving average price is $37.65 and its 200 day moving average price is $41.90.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, beating the consensus estimate of $0.49 by $0.01. The firm had revenue of $806.10 million for the quarter, compared to analyst estimates of $799.70 million. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The company’s revenue was up 12.4% on a year-over-year basis. During the same period in the prior year, the company earned $0.51 EPS. On average, equities research analysts forecast that Hologic, Inc. will post $2.01 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This article was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2017/10/14/lawrence-m-levy-sells-9596-shares-of-hologic-inc-holx-stock.html.
Several institutional investors have recently made changes to their positions in the company. Capital World Investors bought a new position in Hologic during the 2nd quarter worth approximately $312,441,000. HealthCor Management L.P. bought a new position in Hologic during the 2nd quarter worth approximately $76,604,000. Columbus Circle Investors bought a new position in Hologic during the 2nd quarter worth approximately $54,511,000. Vanguard Group Inc. grew its position in Hologic by 4.2% during the 2nd quarter. Vanguard Group Inc. now owns 29,547,138 shares of the medical equipment provider’s stock worth $1,340,850,000 after acquiring an additional 1,200,825 shares during the last quarter. Finally, Koch Industries Inc. grew its position in Hologic by 15,554.1% during the 2nd quarter. Koch Industries Inc. now owns 1,149,481 shares of the medical equipment provider’s stock worth $1,125,000 after acquiring an additional 1,142,138 shares during the last quarter. Hedge funds and other institutional investors own 96.38% of the company’s stock.
HOLX has been the topic of a number of recent analyst reports. Goldman Sachs Group, Inc. (The) cut Hologic from a “conviction-buy” rating to a “buy” rating and decreased their price target for the stock from $48.00 to $47.00 in a research report on Thursday, August 3rd. Stifel Nicolaus restated a “buy” rating on shares of Hologic in a research report on Friday, July 14th. BidaskClub cut Hologic from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Zacks Investment Research cut Hologic from a “hold” rating to a “sell” rating in a research report on Wednesday, July 12th. Finally, Jefferies Group LLC restated a “buy” rating and issued a $49.00 price target on shares of Hologic in a research report on Wednesday, June 28th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and nine have given a buy rating to the company’s stock. Hologic presently has an average rating of “Hold” and a consensus price target of $47.77.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.